[HTML][HTML] Advances in single-cell RNA sequencing and its applications in cancer research
D Huang, N Ma, X Li, Y Gou, Y Duan, B Liu… - Journal of hematology & …, 2023 - Springer
Cancers are a group of heterogeneous diseases characterized by the acquisition of
functional capabilities during the transition from a normal to a neoplastic state. Powerful …
functional capabilities during the transition from a normal to a neoplastic state. Powerful …
Diffuse large B-cell lymphoma
M Martelli, AJM Ferreri, C Agostinelli, A Di Rocco… - Critical reviews in …, 2013 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
[PDF][PDF] Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
WH Wilson, GW Wright, B Hodkinson… - Cancer cell, 2021 - cell.com
In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma
GS Nowakowski, A Chiappella… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
Based on the profile of genetic alterations occurring in tumor samples from selected diffuse
large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies …
large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies …
[PDF][PDF] Genetic and functional drivers of diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous
disease. Transcriptomic and genetic characterization of DLBCL has increased the …
disease. Transcriptomic and genetic characterization of DLBCL has increased the …
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
B cell receptor (BCR) signalling has emerged as a therapeutic target in B cell lymphomas,
but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a …
but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a …
[HTML][HTML] Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype
Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict.
Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype …
Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype …